Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies

Current Pharmaceutical Design

Volumn 10, Issue 13, 2004, Pages 1439-1455

  Haubner, Roland ^a   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiogenesis; Imaging; Integrin; MMP; PET; RGD; SPECT

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA5 INTEGRIN; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ARGINYLGLYCYLASPARTIC ACID; BETA3 INTEGRIN; CARBOHYDRATE DERIVATIVE; CASPASE 3; CASPASE 8; CILENGITIDE; CYCLO(ARGINYLGLYCYLASPARTYL DEXTRO PHENYLVALINE); CYSTEINYLTHREONYLTHREONYLHISTIDYLTRYPTOPHYLGLYCYLPHENYLTHREONYLLEUCYLCYSTEINE; ENDOSTATIN; FIBRONECTIN; GROWTH FACTOR RECEPTOR; IODINE 123; ISOPROTEIN; L 19; LIGAND; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; PEPTIDE DERIVATIVE; PROTEIN ANTIBODY; RECEPTOR; SEMAXANIB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANGIOGENESIS; ANTIGEN BINDING; ANTIGEN EXPRESSION; BINDING AFFINITY; BLOOD VESSEL; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR LIBRARY; MOLECULAR WEIGHT; NON INVASIVE MEASUREMENT; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR MODEL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DIAGNOSTIC IMAGING; DRUG EVALUATION; HUMANS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RADIOACTIVE TRACERS; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 2342439574     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384745     Document Type: Review

References (110)

1. Albert R, Marbach P, Bauer W, Briner U, Fricker G, Bruns C, et al. SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. Life Sci 1993; 53: 517-525.
2. Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, et al. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem 2003; 46: 2376-2396.
3. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 2001; 40: 2373-2378.
4. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991; 291: 50-54.
5. Batt DG, Petraitis JJ, Houghton GC, Modi DP, Cain GA, Corjay MH, et al. Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3). J Med Chem 2000; 43: 41-58.
6. Bishop GG, McPherson JA, Sanders JM, Hesselbacher SE, Feldman MJ, McNamara CA, et al. Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 2001; 103: 1906-1911.
7. Bock M, Bruchertseifer F, Haubner R, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M, et al. Tc-99m-, Re-188- and Y-90-Labeled aVb3 Antagonists: Promising Tracer for Tumor-Induced Angiogenesis. J Nucl Med 2000; 41: 41P.
8. Carmeliet, P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000: 407: 249-257.
9. Castellani P, Dorcaratto A, Pau A, Nicola M, Siri A, Gasparetto B, et al. The angiogenesis marker ED-B+ fibronectin isoform in intracranial meningiomas. Acta Neurochir 2000; 142: 277-282.
10. Chavakis E, Riecke B, Lin J, Linn T, Bretzel RG, Preissner KT, et al. Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. Diabetologia 2002; 45: 262-267.
11. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621-1630.
12. De Jong M, Bernard HF, Breeman WA, Srinivasan A, Schmidt MA, Krenning E P, et al. A Radiolabeled Cyclic RGD-DTPA-Octreotate Analog for Tumor Imaging and Radionuclide Therapy. J Nucl Med 2001; 42: 111P.
13. De Jong M, VanHagen PM, Breeman WA, Bernard HF, Schaar M, VanGameren A, et al. Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy. J Nucl Med 2000; 41: 232P.
14. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001; 28: 534-539.
15. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J Sci Am 2000; 6: S245-249.
16. Ellis LM, Liu W, Fan F, Jung YD, Reinmuth N, Stoeltzing O, et al. Synopsis of angiogenesis inhibitors in oncology. Oncology 2002; 16: 14-22.
17. Fei X, Zheng QH, Hutchins GD, Liu X, Stone KL, Carlson KA, et al. Synthesis of MMP inhibitor radiotracers [11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents. J Label Compd Radiopharm 2002; 45: 449-470.
18. Fei X, Zheng QH, Liu X, Wang JQ, Sun HB, Mock BH, et al. Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. Bioorg Med Chem Lett 2003; 13: 2217-2222.
19. Fei X, Zheng Q-H, Liu X, Wang J-Q, Stone KL, Miller KD, et al. Synthesis of MMP inhibitor radiotracer [11C]CGS 25966, a new potential PET tumor imaging agent. J Label Compd Radiopharm 2003; 46: 343-351.
20. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992; 89: 2018-2022.
21. Foda HD, Zucker S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 2001; 6: 478-482.
22. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
23. Furumoto S, Iwata R, Ido T. Design and synthesis of fluorine-18 labeled matrix metalloproteinase inhibitors for cancer imaging. J Label Compd Radiopharm 2002; 45: 975-986.
24. Furumoto S, Takashima K, Kubota K, Iwata R, Ido T, Fukuda H. Development of a new 18F-labeled matrix metalloproteinase-2 inhibitor for cancer imaging by PET. J Nucl Med 2002; 43: 364P.
25. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson, UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
26. Gurrath M, Muller G, Kessler H, Aumailley M, Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem 1992; 210: 911-921.
27. Hagedorn M, Bikfalvi A. Target molecules for anti-angiogenic therapy: from basic research to clinical trials. Crit Rev Oncol Hematol 2000; 34: 89-110.
28. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002; 16: 1802-1804.
29. Harris TD. personal communication.
30. Harris TD, Kalogeropoulos S, Nguyen T, Liu S, Bartis J, Ellars C, et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 2003; 18: 627-641.
31. Haubner R, Bruchertseifer F, Bock M, Kessler H, Schwaiger M, Wester HJ. Synthesis and biological evaluation of a 99mTc-labelled cyclic RGD-peptide for imaging the avb3 expression. Nucl Med 2004; 43: 26-32.
32. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin avb3 Antagonists. J Am Chem Soc 1996; 118: 7461-7472.
33. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, et al. [F-18]Galacto-RGD: Synthesis, radiolabeling, metabolic stability and radiation dose estimates. Bioconjugate Chem 2004; 15: 61-69.
34. Haubner R, Sulyok G, Weber W, Linke W, Bodenstein C, Wester HJ, et al. Synthesis and first evaluation of [I-123]Aza-RGD-1: a radiolabeled RGD-Mimetic for the noninvasive determination of alpha(v)beta3 integrin expression. Eur J Nucl Med 2001; 28: 1175.
35. Haubner R, Thumshirn G, Weber WA, Herz M, Linke W, Bodenstein C, et al. Noninvasive Determination of Alpha(v) Beta3 Expression Using the Radiolabeled RGD-Mimetic [F-18]GBHO-2. J Label Compd Radiopharm 2003; 46: S4.
36. Haubner R, Kuhnast B, Wester HJ, Weber WA, Huber R, Senekowitsch-Schmidtke R, et al. [F-18]-RGD-Peptides Conjugated with Hydrophilic Tetrapeptides for the Noninvasive Determination of the Alpha(v)beta3 Integrin. J Nucl Med 2002; 43: 89P.
37. Haubner R, Wester HJ, Bock M, Senekowitsch-Schmidtke R, Herz M, Reuning U, et al. Comparison of Tumor Uptake and Biokinetics of I-125- and F-18-Labeled RGD-Peptides. J Label Compd Radiopharm 1999; 42: S36-S38.
38. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42: 326-336.
39. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999; 40: 1061-1071.
40. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61: 1781-1785.
41. Heath EI, Grochow LB. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 2000; 59: 1043-1055.
42. Henry C, Moitessier N, Chapleur Y. Vitronectin receptor alpha(v)beta(3) integrin antagonists: chemical and structural requirements for activity and selectivity. Mini Rev Med Chem 2002; 2: 531-542.
43. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-193.
44. Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 1994; 14: 246-258.
45. Hoekman K. SU6668, a multitargeted angiogenesis inhibitor. Cancer J 2001; 7: S134-138.
46. Hynes R. Molecular biology of fibronectin. Annu Rev Cell Biol 1985; 1: 67-90.
47. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002; 8: 918-921.
48. Hynes RO, Bader BL, Hodivala-Dilke K. Integrins in vascular development. Braz J Med Biol Res 1999; 32: 501-510.
49. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 1996; 87: 602-611.
50. Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, et al. Tumor targeting with radiolabeled alpha(v) beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002; 62: 6146-6151.
51. Janssen MLH, Boerman OC, Edwards DS, Barnett JA, Rajopadhye WJ, Oyen G, et al. 111In and 99mTc labeled peptides against the avb3 integrin: A new target for radionuclide peptide targeting of tumors. J Nucl Med 2000; 41: 33P.
52. Janssen MLH, Oyen WJG, Massuger LFAG, Frielink C, Dijkgraaf I, Edwards DS, et al. Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor Imaging. Cancer Biother Radiopharm 2002; 17: 641-646.
53. Kerr JS, Slee AM, Mousa SA. Small molecule alpha(v) integrin antagonists: novel anticancer agents. Expert Opin Investig Drugs 2000; 9: 1271-1279.
54. Kerr JS, Slee AM, Mousa SA. The alpha(v) integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs 2002; 11: 1765-1774.
55. Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J Med Chem 1999; 42: 1723-1738.
56. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999; 17: 768-774.
57. Kuhnast B, Bodenstein C, Haubner R, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M, et al. Targeting of gelatinase activity with a rediolabelled cyclic HWGF peptide. Nucl Med Biol 2004; in press.
58. Kuhnast B, Bodenstein C, Wester HJ, Haubner R, Schwaiger M, Weber W. Carbon-11 labelling of a N-sulfonylamino acid derivative for MMP-2 and MMP-9 imaging. Eur J Nucl Med 2002; 29: S76.
59. Kuhnast B, Bodenstein C, Wester HJ, Weber WA. Carbon-11 labelling of a N-sulfonylamino acid derivative: a potential tracer for MMP-2 and MMP-9 imaging. J Label Compd Radiopharm 2003; 46: 1093 - 1103.
60. Kuhnast B, Haubner R, Wester H-J, Bodenstein C, Schwaiger M, Weber WA. In vivo Evaluation of a labeled decapeptide to image gelatinase activity. J Nucl Med 2002; 43: 370P.
61. Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T, et al. Angiogenesis factors. Intern Med 2001; 40: 565-572.
62. Lee BC, Sung HJ, Song SH, Choe YS, Lee K-H, Chung K-H, et al. ynthesis of Technetium-99m Labeled Glucosamino-Asp-Lys-Arg-Gly-Asp-D-Phe as a Potential Tumor Imaging Agent. J Label Compd Radiopharm 2003; 46: S106.
63. Leisner M, Kessler H, Schwaiger M, Wester HJ. Synthesis of Na-D-Phel-Amadori Derivatives of Tyr3-Octreotide: Precursor for 123I- / 18F-Labelled SSTR-Binding SPECT/PET Tracers with Improved Biodistribution. J Label Compd Radiopharm 1999; 42: S549-S551.
64. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, et al. Phase I and pharmacological study of the oral matrix etalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001; 7: 1912-1922.
65. Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, et al. Matrix metalloproteinase inhibitors: a structure-activity study. J Med Chem 1998; 41; 199-223.
66. Li WP, Lewis JS, Lan S, Anderson CJ. 64Cu-Dota-CTTHWGF TLC, a selective gelatinase inhibitor for tumor imaging. J Nucl Med 2002; 43: 277P.
67. Liu S, Cheung E, Ziegler MC, Rajopadhye M, Edwards DS. (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug Chem 2001; 12: 559-568.
68. Liu S, Edwards DS, Ziegler MC, Harris AR, Hemingway SJ, Barrett JA. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem 2001; 12: 624-629.
69. Liu S, Harris TD, Ellars CD, Edwards DS. Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist. Bioconjugate Chem 2003; 14: 1030 - 1037.
70. Marastoni M, Spisani S, Tomatis R. Synthesis and biological activity of d-glycopyranosyl peptide T derivatives. Arzneimittelforschung / Drug Res 1994; 44: 984-987.
71. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001; 6: 1005-1024.
72. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000; 15: 29-41.
73. Michael K, Wittmann V, König W, Sandow J, Kessler H. S- and C-glycopeptide derivatives of an LH-RH agonist. Int J Peptide Protein Res 1996; 48: 59-70.
74. Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, et al. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem 2000; 43: 22-26.
75. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 2000; 87: 716-723.
76. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 1997; 15: 1271-1275.
77. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 33; 2001: 960-970.
78. Ogawa M, Hatano K, Oishi S, Kawasumi Y, Fujii N, Kawaguchi M, et al. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta(3) integrin related tumor imaging. Nucl Med Biol 2003; 30: 1-9.
79. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, et al. Pilot study of vitaxin - an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 2001; 92: 1347-1348.
80. Pelmenschikov V, Siegbahn PE. Catalytic mechanism of matrix metalloproteinases: two-layered ONIOM study. Inorg Chem 2002; 41: 5659-5666.
81. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-1117.
82. Pfaff M, Tangemann K, Muller B, Gurrath M, Muller G, Kessler H, et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem 1994; 269: 20233-20238.
83. Pitts WJ, Wityak J, Smallheer JM, Tobin AE, Jetter JW, Buynitsky JS, et al. Isoxazolines as potent antagonists of the integrin alpha(v)beta(3). J Med Chem 2000; 43: 27-40.
84. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, et al. Two-step methodology for high-yield routine radiohallogenation of peptides: 18F-labelled RGD- and octreotide analogs. J Nucl Med 2004; in press.
85. Poethko T, Thumshirn G, Hersel U, Rau F, Haubner R, Schwaiger M, et al. Improved tumor uptake, tumor retention and tumor/background ratios of pegylated RGD-multimers. J Nucl Med 2003; 44: 46P.
86. Quirt I, Bodurth A, Lohmann R, Rusthoven J, Belanger K, Young V, et al. Phase II study of marimastat (BB-2516) in malignant melanoma: A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2002; 20: 431-437.
87. Rosen LS. Inhibitors of the vascular endothelial growth factor receptor. Hematol Oncol Clin North Am 2002; 16: 1173-1187.
88. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic Detection of the ED-B Domain of Fibronectin, a Marker of Angiogenesis, in Patients with Cancer. Clin Cancer Res 2003; 9: 571-579.
89. Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of Pharmacokinetics of Radioiodinated Tyr3-Octreotide by Conjugation with Carbohydrates. Bioconjugate Chem 2002; 13: 1021 -1030.
90. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G, et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med 1998; 25: 1383-1389.
91. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999; 103: 47-54.
92. Su ZF, He J, Rusckowski M, Hnatowich DJ. In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands. Nucl Med Biol 2003; 30: 141-149.
93. Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich DJ. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. Bioconjug Chem 2002; 13: 561-570.
94. Sulyok GA, Gibson C, Goodman S, Holzemann G, Wiesner M, Kessler H. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists. J Med Chem 2001; 44: 1938-1950.
95. Sung HJ, Lee BC, Song SH, Lee SY, Choe YS, Lee K-H, et al. Synthesis of Fluorine-18 Labeled Glucosamino-(4-Fluorobenzyl)-Asp-Lys-Arg-Gly-Asp-D-Phe as a Potential Tumor Imaging Agent. J Label Compd Radiopharm 2003; 46: S126.
96. Sutcliffe-Goulden JL, O'Doherty MJ, Marsden PK, Hart IR, Marshall JF, Bansal SS. Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging 2002; 29: 754-759.
97. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999; 94: 192-198.
98. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry 2003; 9: 2717-2725.
99. Tucker GC. Inhibitors of integrins. Curr Opin Pharmacol 2002; 2: 394-402.
100. van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging-and radionuclide therapy. Int J Cancer 2000; 90: 186-198.
101. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99; 2002: 157-166.
102. Wester HJ, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau FC, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel (18)F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003; 30: 117-122.
103. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging 2002; 29: 28-38.
104. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
105. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
106. Zheng QH, Fei X, DeGrado TR, Wang JQ, Lee Stone K, Martinez TD, et al. Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [(11)C]methyl ester. Nucl Med Biol 2003; 30: 753-760.
107. Zheng QH, Fei X, Liu X, Wang JQ, Bin Sun H, Mock BH, et al. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 2002; 29: 761-770.
108. Jackson DY. Alpha 4 integrin antagonists. Curr Pharm Design 2002; 8(14): 1229-53.
109. Pearlman JD, Laham RJ, Post M, Leiner T, Simons M. Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis. Curr Pharm Design 2002; 8(16): 1467-96.
110. Vailhe B, Feige JJ. Thrombospondins as anti-angiogenic therapeutic agents. Curr Pharm Design 2003; 9(7): 583-8.